4D Molecular Therapeutics (FDMT)
(Delayed Data from NSDQ)
$9.97 USD
-0.37 (-3.58%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $9.99 +0.02 (0.20%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
FDMT 9.97 -0.37(-3.58%)
Will FDMT be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for FDMT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FDMT
4D Molecular Therapeutics (FDMT) Loses -26.01% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Wall Street Analysts Think 4D Molecular Therapeutics (FDMT) Could Surge 225.1%: Read This Before Placing a Bet
FDMT: What are Zacks experts saying now?
Zacks Private Portfolio Services
4D Molecular Therapeutics (FDMT) Loses -21.87% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Lags Revenue Estimates
Carisma Therapeutics Inc. (CARM) Reports Q2 Loss, Tops Revenue Estimates
Other News for FDMT
4D Molecular Therapeutics: Market Expects Wet AMD Gene Therapy Failure - I'm Not So Sure
4D Molecular Therapeutics downgraded at Cantor following wet AMD asset data
Janus Henderson Global Life Sciences Diversified ADR Managed Account Q2 2024 Commentary
4DMT Announces Presentation at the 2024 North American Cystic Fibrosis Conference
Janus Henderson Global Life Sciences Fund Q2 2024 Commentary